GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » Gross Margin %

2seventy bio (2seventy bio) Gross Margin % : 70.54% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. 2seventy bio's Gross Profit for the three months ended in Dec. 2023 was $7.5 Mil. 2seventy bio's Revenue for the three months ended in Dec. 2023 was $10.7 Mil. Therefore, 2seventy bio's Gross Margin % for the quarter that ended in Dec. 2023 was 70.54%.

Warning Sign:

2seventy bio Inc gross margin has been in long-term decline. The average rate of decline per year is -5.9%.


The historical rank and industry rank for 2seventy bio's Gross Margin % or its related term are showing as below:

TSVT' s Gross Margin % Range Over the Past 10 Years
Min: 59.82   Med: 88.22   Max: 98.38
Current: 83.15


During the past 6 years, the highest Gross Margin % of 2seventy bio was 98.38%. The lowest was 59.82%. And the median was 88.22%.

TSVT's Gross Margin % is ranked better than
77.87% of 741 companies
in the Biotechnology industry
Industry Median: 59.43 vs TSVT: 83.15

2seventy bio had a gross margin of 70.54% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for 2seventy bio was -5.90% per year.


2seventy bio Gross Margin % Historical Data

The historical data trend for 2seventy bio's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio Gross Margin % Chart

2seventy bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial 93.28 97.83 59.82 71.34 83.15

2seventy bio Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.00 89.68 87.47 58.79 70.54

Competitive Comparison of 2seventy bio's Gross Margin %

For the Biotechnology subindustry, 2seventy bio's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2seventy bio's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2seventy bio's Gross Margin % distribution charts can be found below:

* The bar in red indicates where 2seventy bio's Gross Margin % falls into.



2seventy bio Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

2seventy bio's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=83.5 / 100.387
=(Revenue - Cost of Goods Sold) / Revenue
=(100.387 - 16.918) / 100.387
=83.15 %

2seventy bio's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=7.5 / 10.684
=(Revenue - Cost of Goods Sold) / Revenue
=(10.684 - 3.147) / 10.684
=70.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


2seventy bio  (NAS:TSVT) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

2seventy bio had a gross margin of 70.54% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


2seventy bio Gross Margin % Related Terms

Thank you for viewing the detailed overview of 2seventy bio's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


2seventy bio (2seventy bio) Business Description

Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Lin Wei director C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938